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ABSTRACT
Objective: Invasive cervical cancer (ICC) and HIV are common in sub-Sahara Africa. 
Both ICC and HIV are immunosuppressive, and are associated with decreased CD4 
and CD8 profiles. In a group of women with ICC starting radiotherapy, we determined 
their CD4 profiles.
Design: A cross-sectional study.
Settings: Kenyatta National Hospital, Nairobi, Kenya, radiotherapy unit. 
Subjects: Women with invasive cervical cancer (344) seeking radiotherapy treatment 
for the first time between January 2000 and March 2003, had blood samples analyzed 
for CD4 and CD8 cell counts by flow cytometry. Haemoglobin, white cell count, 
lymphocyte and platelet counts were determined using coulter machine. All patients 
had received pre- and post HIV counseling.
Results: The mean age was 49+13 years. About 13.1% of the women with ICC were 
HIV positive. Overall, mean and median CD4 cell count was 829+355 cells/mm3 and 
792 cells/mm3. Among HIV+ patients, mean and median CD4 cell counts were 451+288 
cells/mm3 and 405 cells/mm3 respectively. The mean CD4 cell count for the HIV+ 
women was 886+329 cells/mm3 with median of 833 cells/mm3, range 147-2065 cells/mm3. 
Only nine (20%) of the 45 HIV+ women had CD4 cell count of 0-200.  HIV+ women 
had lower CD4 percentage and  cell count and higher CD8 percentage and cell count 
as compared to HIV negative women, p < 0.001. HIV infection was significantly and 
independently associated with high proportion of women who had CD4 cell count of 
less than 200 cells/mm3 or less than 350 cells/mm3, p < 0.0001.
Conclusions: Women with ICC and concurrent HIV infection have decreased CD4 cell 
subset. These results suggest HIV infection may be associated with more severe CD4 
depletion in women with ICC. 
INTRODUCTION
Invasive cervical cancer (ICC) is common in 
populations with high HIV prevalence in sub-Sahara 
Africa (1,2). Depressed systemic as well as local 
immune responses have been observed in patients 
with advanced cervical cancer (3,4). Patients with 
iatrogenic CD4 cell depression following organ 
transplant develop malignancies among them ICC (5). 
T-lymphocyte derangements seem to be an important 
component in ICC tumorigenesis pathway. ICC 
and HIV are both immunosuppressive conditions 
which theoretically may be associated with profound 
immunosupression when they coexist.
 The fundamental abnormality in women with 
HIV infection is T-lymphocyte derangement with 
decreased CD4cells. HIV is associated with increased 
risk of human papilomavirus (HPV) - associated 
cancers of the cervix (6), anus, oropharynx, penis, 
vagina and vulva (7).  HIV infection is also associated 
with early onset of ICC (8,9).  Other than the effect 
of immunosuppression from HIV infection in 
increasing standardised incidence ratios (SIRs) (7), 
in vitro studies suggest the HIV encoded tat protein 
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may enhance the expression of HPV E6- and E7-
transforming proteins (10) or cell cycle progression 
(11) leading to development of ICC. 
 CD4 enumeration is important for the evaluation 
of HIV disease stage and progression. In resource 
limited environments, CD4 determination is the 
biomarker commonly used by clinicians together with 
the World Health Organization (WHO). HIV clinical 
staging system helps to decide when to initiate HIV 
infected patients on treatment as well as monitor 
the progress of treatment. Though there are several 
studies documenting CD4 and CD8 values in healthy 
individuals (12-14), such data is lacking for women 
with ICC. This study was undertaken to determine 
CD4 T-lymphocyte subsets in patients with ICC in 
Kenya.
MATERIALS AND METHODS
This cross-sectional study was conducted from 
January 2000 to March 2003 at the radiotherapy unit 
of Kenyatta National Hospital (KNH). Only patients 
seeking radiotherapy treatment for cervical cancer for 
the first time were included. All enrolled participants 
received HIV pre-test and post-test counseling and 
gave informed consent. A blood sample was obtained 
for HIV testing using enzyme-linked immunoassay 
(ELISA) (Biochem Immuno Systems Kit, Montreal, 
Canada) and positive samples were confirmed using 
double ELISA (Biotech Ltd, Cambridge, Ireland). 
From all enrolled patients, blood was obtained for 
CD4 and CD8 cell count using flow cytometry (FAC 
scan, Becton-Dickson). Flow cytometry is an accepted 
standard method for determination of absolute count 
of CD4, CD8+ T-lymphocytes.15 Blood specimens 
were collected by venipuncture in anticoagulated 
K-3 liquid vacutainer specimen bottle (Becton 
Dickson, Mountain View CA) between 9-12AM. 
CD4/CD8 absolute cell counts and their ratios were 
determined by two colour immunophenotyping 
on single platform fluorescence activated cells 
sorting (FACS) count system, using fluorochrome 
labeled monoclonal antibodies strictly following 
the manufacturers’ instructions. Total white blood 
cell counts (WBCs), and hemoglobin values were 
determined using a Coulter machine. Study staff 
administered a structured questionnaire.
 Statistical analysis was carried out using SPSS 
version 13.0 (SPSS Inc. Chicago, Illinois, USA) 
statistical package. Fisher exact test and Yates 
corrected Chi-square testing was used to compare 
proportions. Differences between means were tested 
by t-test. Odds ratio (OR) and 95% confidence interval 
(CI) was used to measure strength of associations. 
Multivariate logistic regression models included 
variables significant in univariate analysis or those 
that may have biological influence on the dependent 
variable. A P value (two-tailed test) of <0.05 was 
considered significant. All study participants gave 
informed consent. This study was reviewed and 
approved by KNH/University of Nairobi ethics and 
research committee before commencement.
RESULTS
None of the patients approached to participate in the 
study declined. A total of 344 patients with invasive 
cervical cancer (ICC) were evaluated. Table 1 shows 
sociodemographic characteristics. The mean age 
was 49+13, range 22-94 years. About 13.1% (45/344) 
women were HIV positive. Women less than 35 years, 
were eight times more likely to have HIV infection 
than women >35 years old (43.8% vs 8.3%, OR 8.6, 
95% CI 4.2-17.5, p<0.001).
Table 1

















None: Zero years 102 30
Primary: 1-7/8 years 183 54
Secondary: 8-12 years 56 17










Family planning use (343)
Yes 172 50
No 171 50
 The mean CD4 cell count for the HIV negative 
women was 886+329 cells/mm3 with median of 833 
cells/mm3, range 147-2065 cells/mm3 as compared 
to mean CD4 cell count of 451+288 cells/mm3 with 
median of 405 cells/mm3, range 17-1275 cells/mm3 
for the HIV positive women, p<0.001. Of the 45 HIV 
positive women, nine (20%) had CD4 cell count 
of 0-200 compared to only 2 (0.7%) of the 299 HIV 
negative women (OR 37, 95% CI 7.7-166.7, p<0.0001). 
Using the revised WHO CD4 cell count criteria for 
initiation of HIV treatment, 18 (40%) of the 45 HIV 
positive women had CD4 cell count of 0-350 compared 
to nine (3%) of the 301 women who were HIV negative 
(OR 21, 95% CI 8.8-53, p<0.0001).
 Table 2 shows selected parameters by HIV status. 
HIV positive women were significantly different from 
HIV negative women in most of the parameters except 
WBC, platelet count and lymphocyte percentage 
which were similar. HIV negative women had 
significantly lower CD4 percentage and count and 
higher CD8 percentage and count than HIV negative 
women, p<0.001. 
Table 2
Comparion of selected numerical data among HIV positive and negative women 
Variable HIV+ HIV- P value
Age in years 37.0 ± 9.0 50.0 ± 13.0 <0.001
CD4 percentage 19.0 ± 11.0 38.0 ± 8.0 <0.001
CD4 count 451.0 ± 288.0 885.0 ± 329.0 <0.001
CD8 percentage 53.0 ± 15.0 28.0 ± 9.0 <0.001
CD8 count 1378.0 ± 776.0 680.0 ± 392.0 <0.001
CD4/CD8 ratio 0.5 ± 0.5 1.5 ± 0.7 <0.001
WBC 7.4 ± 2.6 8.6 ± 4.4 0.091
Hemoglobin 9.0 ± 3.0 11.0 ± 2.0 <0.001
Platelets 312.0 ± 151.0 360.0 ± 155.0 0.052
Lymphocyte percentage 32.0 ± 14.0 31.0 ± 11.0 0.308
SD-standard deviation; WBC-While blood cells; ICC-Invasive cervical cancer
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In univariate analysis, being HIV positive, reporting 
ever use of condoms for STD protection, reporting 
ever use of alcohol, and being younger than 40 years 
of age were significantly associated with severe 
immunossuppression, Table 3. In multivariate 
analyses adjusting simultaneously for age, age of 
first intercourse, condom use for STD protection, 
history of ever having had an STD, alcohol use, and 
number of viable pregnancies, being HIV positive 
and reporting ever use of alcohol was significantly 
and independently associated with high proportion 
of women with severe immunuossuppression (CD4 
cell count of 0-200 cells/mm3), Table 4. The same 
findings were obtained if CD4 cell count classification 
was changed to the new class of 0-350 cells/mm3 and 
more than 350 cells/mm3 (data not shown). 
Table 3
Univariate analysis of factors associated with CD4 cell count for women with Invasive cervical cancer 
Variable CD4 cell count OR 95%CI p value
0-200 201+
HIV
Positive 9 20 36 80 37 8-167 <0.0001
Negative 2 1 297 99
Age in years
>41 4 2 229 98 4.1 1-14 0.039
<40 7 7 97 93
Marital status
Single 2 8 24 93 0.6–14.0 0.175
Married or ever married 9 3 309 97 2.9
Education attainment
None 2 2 100 98 0.5 0.1–2.1 0.397
Any level of education 9 4 233 96
Alcohol use
Yes 4 16 21 84 8.5 2.3–31.3 0.005
No 10 3 305 97
Smoking
Yes 1 4 27 96 1.1 0.1–9.2 0.909
No 10 3 305 97
Ever had an STD
Yes 3 6 44 94 2.5 0.6–9.6 0.183
No 8 3 288 97
Ever used condoms for STD 
protection
Yes 5 10 46 90 5.1 1.5–17.5 0.014
No 6 2 283 98
Ever use of family planning
Yes 8 5 164 95 2.7 0.7–10.5 0.138
No 3 2 168 98
Age at menarche
Up to 15 years 9 5 187 95 3.3 0.7–15.5 0.131
16+ years 2 1 137 99
Age at first sex
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Up to 18 years 8 3 228 97 1.1 0.3–4.2 0.903
19+ years 3 3 93 97
Age at first pregnancy
Up to 19 years 9 5 176 95 3.9 0.8–18.4 0.072
20+ years 2 1 157 99
Age at first child
Up to 19 years 9 5 171 95 4.1 0.8–19.4 0.067
20+ years 2 1 157 99
Number of viable 
pregnancies
0-4 5 5 97 95 2.0 0.6–6.7 0.315
5+ 6 3 234 96
OR Odds ratio; CI Confidence interval, STD Sexually transmitted infections/diseases
Table 4
 Multivariate analysis of factors associated with CD4 cell count for women with Invasive cervical cancer 
Variable AOR 95%CI p value
Being HIV positive 35.7 7.4-166.7 <0.0001
Age less than 40 years 0.6 0.1-3.4 0.532
Being never married ever 1.3 0.2-9.1 0.175
Reporting ever use of alcohol 5.5 1.2-25.0 0.027
Reporting history of ever smoking 1.3 0.1-13.4 0.851
Reporting history of ever having had an STD 2.1 0.4-12.0 0.405
Ever used condoms for STD protection 0.9 0.2-4.6 0.929
Age at first sex up to 18 years 0.6 0.1-3.4 0.588
5 or more viable pregnancies 0.6 0.1-3.2 0.527
AOR Adjusted odds ratio; CI Confidence interval, STD Sexually transmitted diseases.
DISCUSSION
Sub-Saharan countries, including Kenya, are 
characterised by high prevalence of HIV infection 
and high incidence of ICC. In such settings, HIV and 
ICC are common concurrent conditions. Invasive 
cervical cancer (ICC) is one of the three acquired 
immunodeficiency syndrome (AIDS) – defining 
cancers. Women who are HIV infected with ICC 
qualify to be initiated on HIV treatment. However, 
treating cancer and HIV in women with concurrent 
problems is likely to be a challenge because of potential 
drug interactions, side effects and potential negative 
effect of chemotherapy on CD4 count and HIV viral 
load (16, 17). 
 HIV treatment is now readily available in Kenya 
with treatment progress being principally monitored 
by CD4 determination. In our study, women with ICC 
and HIV+ had CD4 counts and percentage that were 
significantly lower than in women with ICC not HIV 
infected. These findings are similar to reports from 
other studies (18, 19). In Park and Kim's study, 18 
out of 34 patients with ICC from Yonsei University, 
South Korea showed that ICC patients had lower 
CD4 percentage (36.3+10.1) as compared to controls 
(45.6+8.9, p<0.05). 
 In our study, the percentage of patients with 
CD4 cell count <200 cells/mm3 were few, nine 
women (20.0%) and those with CD4 cell count <350 
cells/mm3 were 18 women (40%). These findings do 
suggest that women with ICC and concurrent HIV 
infection included in this study did not have severe 
immunosuppression. One would have expected to 
find severe immunosuppresion among ICC patients 
co-infected with HIV as compared to women without 
HIV infection, given that ICC and HIV are both 
immunossuppressive. A study by Leitao et al (20) in 
America, among 15 women with ICC and concurrent 
HIV infection demonstrated statistically significant 
lower CD4 cell count of 208 cell/microL in women 
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with ICC as compared to 445 cell/microL in women 
without ICC but HIV infected. There are notable 
differences in immunological status between the two 
study populations. In the study by Leitao et al (20), 
only 7% (1/15) of the patients had CD4 cell counts 
more than 200 while in our study 80% had CD4 cell 
count greater than 200. Although there is evidence 
that HIV infection is significantly associated with 
rapid progression of ICC lesions (2, 21) the temporal 
relationship of HIV and ICC is not well known. What 
comes first? ICC and premalignant lesions may 
facilitate HIV acquisition by the disruption of vaginal/
cervical epithelium while having HIV infection would 
facilitate persistence of highly oncongenic HPV 
subtypes leading to the development of premalignant 
lesions and ICC. Therefore, the lack of demonstration 
of severe immunosuppression among ICC patients in 
our study was an unexpected finding. It is possible 
that these patients may have acquired HIV infection 
while they had cervical cancer accounting for the low 
degree of immunosuppression observed. The patients 
included in this study may be a cohort which has 
survived the tragedy of having the dual problem. 
Although all the ICC patients included in the study 
were in WHO stage 4 at the time of the study, none 
were not on HIV treatment. This was due to the lack 
of HIV treatment services in public health facilities in 
Kenya. This situation has changed and antiretroviral 
therapy medicines (ARVs) are now readily available.
 The finding of no severe immunosuppression 
among ICC with HIV co-infection is significant for 
clinicians caring for women with ICC and concurrent 
HIV infection. From these results, CD4 cell count 
would be of value in women with ICC for monitoring 
HIV treatment response. Interpretation of CD4 counts, 
however, has to take into account the fact that CD4 
cell count decrease when women with ICC are on 
radiotherapy/chemotherapy treatment with full 
recovery after treatment (16, 17).  
 The present study is subject to some limitations. 
This study was conducted at a tertiary facility 
located at the capital city which may have limited 
access for patients from far distances resulting in a 
biased population. Kenyatta National Hospital is the 
only public facility offering radiotherapy in Kenya. 
Another possible limitation of our study was its 
observational design. The dates of HIV infection in 
the women included in the study was unknown.
In conclusion, the results of this study show significant 
decrease in CD4 cell count among women with 
ICC and HIV co-infection. The expected severe 
immunosuppression in women with ICC and HIV 
infection was not demonstrated in this study. CD4 
cell count determination can therefore be used in 
monitoring HIV treatment in women with ICC and 
HIV infection. Prospective cohort study including 
women with known dates of HIV infection will be 
needed to elucidate the relationship between ICC and 
HIV co-infections on the CD4 cell count.
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